Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference


CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that Michel Dahan, President and Chief Executive Officer, will provide a corporate update and present the latest clinical study results for the company’s investigational oral therapy to prevent blindness in patients with Stargardt disease, during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

Read the original:
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Related Posts